Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon
Surmodics, Inc. (SRDX)
Last surmodics, inc. earnings: 4/29 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
surmodics.gcs-web.com/investor-overview
Company Research
Source: Business Wire
European Journal of Vascular and Endovascular Surgery Publishes Results Showing Comparable Safety and Efficacy of SurVeil™ DCB Despite IN.PACT™ Admiral™ DCB having 75% Higher Paclitaxel Dose. EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil™ drug-coated balloon (DCB) is non-inferior to the IN.PACT™ Admiral™ DCB for safety and efficacy in patients with femoropopliteal arterial disease while using a substantially lower drug dose. The findings were published in the March 2025 edition of the European Journal of Vascular and Endovascular Surgery.1This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422628214/en/Figure 1. SurVeil™ DCB balloon coating (above) vs IN.PACT™ Admiral™ DCB balloon co
Show less
Read more
Impact Snapshot
Event Time:
SRDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRDX alerts
High impacting Surmodics, Inc. news events
Weekly update
A roundup of the hottest topics
SRDX
News
- Surmodics gains as FTC won't appeal denial of GTCR deal injunction [Seeking Alpha]Seeking Alpha
- Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today [Yahoo! Finance]Yahoo! Finance
- Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire TodayBusiness Wire
- Surmodics (NASDAQ:SRDX) was downgraded by analysts at Barrington Research from a "market perform" rating to an "underperform" rating.MarketBeat
- Judge denies FTC's bid to block $627M Surmodics buyout [Yahoo! Finance]Yahoo! Finance
SRDX
Earnings
- 8/8/25 - Beat
SRDX
Sec Filings
- 11/20/25 - Form SCHEDULE
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- SRDX's page on the SEC website